228 related articles for article (PubMed ID: 21864230)
21. Anti-tumor potential of bisphosphonates.
Green JR
Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic approach of primary bone tumours by bisphosphonates.
Moriceau G; Ory B; Gobin B; Verrecchia F; Gouin F; Blanchard F; Redini F; Heymann D
Curr Pharm Des; 2010; 16(27):2981-7. PubMed ID: 20722622
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
Aft R
Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
[TBL] [Abstract][Full Text] [Related]
24. Development of bisphosphonates.
Fleisch H
Breast Cancer Res; 2002; 4(1):30-4. PubMed ID: 11879557
[TBL] [Abstract][Full Text] [Related]
25. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
[TBL] [Abstract][Full Text] [Related]
26. Zoledronic acid: past, present and future roles in cancer treatment.
Saad F
Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
[TBL] [Abstract][Full Text] [Related]
27. New insights into the molecular mechanisms of action of bisphosphonates.
Rogers MJ
Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects.
Teixeira S; Branco L; Fernandes MH; Costa-Rodrigues J
Mini Rev Med Chem; 2019; 19(12):988-998. PubMed ID: 31020940
[TBL] [Abstract][Full Text] [Related]
29. New role for an established drug? Bisphosphonates as potential anticancer agents.
Koul HK; Koul S; Meacham RB
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
[TBL] [Abstract][Full Text] [Related]
30. Combined therapies of bone disease with bisphosphonates.
Syddall SP; Ottewell PD; Holen I
Curr Pharm Des; 2010; 16(27):2988-97. PubMed ID: 20722617
[TBL] [Abstract][Full Text] [Related]
31. Cellular and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
[TBL] [Abstract][Full Text] [Related]
32. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
33. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates in preclinical bone oncology.
Clézardin P; Benzaïd I; Croucher PI
Bone; 2011 Jul; 49(1):66-70. PubMed ID: 21145441
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.
Kimmel DB
J Dent Res; 2007 Nov; 86(11):1022-33. PubMed ID: 17959891
[TBL] [Abstract][Full Text] [Related]
36. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.
Mönkkönen H; Auriola S; Lehenkari P; Kellinsalmi M; Hassinen IE; Vepsäläinen J; Mönkkönen J
Br J Pharmacol; 2006 Feb; 147(4):437-45. PubMed ID: 16402039
[TBL] [Abstract][Full Text] [Related]
37. [Molecular basis of bone metastasis formation and its targeted therapy].
Tímár J
Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development.
Soares AP; do Espírito Santo RF; Line SR; Pinto Md; Santos Pde M; Toralles MB; do Espírito Santo AR
Environ Toxicol Pharmacol; 2016 Mar; 42():212-7. PubMed ID: 26895384
[TBL] [Abstract][Full Text] [Related]
39. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
